Fig. 5: EFS from randomization in patients with stage III N2 or non-N2 NSCLC by number of adjuvant treatment doses.
a–d, EFS from randomization in patients with N2 NSCLC with six or fewer doses of adjuvant treatment (a), patients with N2 NSCLC with more than six doses of adjuvant treatment (b), patients with non-N2 NSCLC with six or fewer doses of adjuvant treatment (c) and patients with non-N2 NSCLC with more than six doses of adjuvant treatment (d). The superscript letter ‘a’ indicates that HRs were not calculated for subgroups with less than ten patients with events. Superscript letters ‘b’ and ‘c’ indicate the following 95% CIs: b, 44–89; c, 10–59. Superscript letter ‘d’ indicates that in the nivolumab arm, 28 patients received the maximum 13 doses of adjuvant treatment, and 13 patients received 7–12 doses; in the placebo arm, 23 patients received 13 doses of adjuvant treatment and 18 patients received 7–12 doses. Superscript letters ‘e’–‘h’ indicate the following 95% CIs: e, 79–98; f, 57–84; g, 33–98; h, NR–NR. Superscript letter ‘i’ indicates that in the nivolumab arm, 22 patients received the maximum 13 doses of adjuvant treatment, and 4 patients received 7–12 doses; in the placebo arm, 24 patients received 13 doses of adjuvant treatment, and 9 patients received 7–12 doses. Superscript letters ‘j’ and ‘k’ indicate the following 95% CIs: j, 73–98; k, 74–97. The HRs and two-sided 95% CIs for comparisons of EFS between the treatment arms were estimated using an unstratified Cox proportional hazards model using the randomized arm as a single covariate. EFS rates at 1 year were estimated using Kaplan–Meier estimates on the EFS curve for each randomized arm.
